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Abstract 
Objective: Various definitions of metabolic health have been proposed to explain differences in the risk of 
type 2 diabetes within body mass index (BMI) categories. The goal of this study was to assess their 
predictive relevance.  
Research Design and Methods: We performed systematic searches of MEDLINE records for prospective 
cohort studies of type 2 diabetes risk in categories of BMI and metabolic health. In a two-stage meta-
analysis, relative risks (RR) specific to each BMI category were derived by network meta-analysis and the 
resulting RRs of each study were pooled using random effects models. Hierarchical summary receiver 
operating characteristic curves were used to assess predictive performance.  
Results: In a meta-analysis of 140,845 participants and 5,963 incident cases of type 2 diabetes from 14 
cohort studies, being classified as metabolically unhealthy was associated with higher relative risk of 
diabetes in all BMI categories (RR compared with healthy individuals [95% confidence interval, CI]: lean, 
4.0 [3.0 – 5.1]; overweight, 3.4 [2.8 – 4.3]; obese, 2.5 [2.1 – 3.0]). Metabolically healthy obese individuals 
had a high absolute risk of type 2 diabetes (10-year cumulative incidence [95% CI]: 3.1% [2.6 – 3.5%]). 
Current binary definitions of metabolic health had high specificity (pooled estimate [95% CI]: 0.88 [0.84 – 
0.91]) but low sensitivity (0.40 [0.31 – 0.49]) in lean individuals and satisfactory sensitivity (0.81 [0.76 – 
0.86]) but low specificity (0.42 [0.35 – 0.49]) in obese individuals. However, positive (< 3.3 in all BMI 
categories) and negative (> 0.4) likelihood ratios were consistent with insignificant to small improvements 
in prediction.  
Conclusions: Although individuals classified as metabolically unhealthy have a higher relative risk of type 
2 diabetes compared with individuals classified as healthy in all BMI categories, current binary definitions 
of metabolic health have limited relevance to the prediction of future type 2 diabetes.  
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  Obesity and the ‘metabolic syndrome’, two highly prevalent and often coexisting 
conditions, are major risk factors for type 2 diabetes and cardiovascular disease (1-3). The 
observation that some obese individuals have a favourable metabolic profile and appear to be 
at low risk of obesity-related complications has led to the notion of ‘metabolically healthy 
obesity’ (4,5). The topic has received much attention in recent times, with an increasing 
number of studies using definitions of metabolic health in body mass index (BMI) categories 
either as a risk factor or an outcome (5-9). 
  In the existing literature, however, there is little consensus on the definitions of 
metabolic health (4). In addition, the relevance of metabolic health definitions to the 
prediction of incident type 2 diabetes in body mass index (BMI) categories has not been 
investigated. 
 Establishing the predictive value of currently used definitions of metabolic health has 
been deemed of primary importance, as an accurate risk classification may justify selective 
preventive action in high-risk individuals (4). In addition, the construct of the ‘metabolic 
syndrome’, which is used as a basis for several definitions of metabolic health, has been 
proposed as a clinically-useful predictor of the risk of future type 2 diabetes (10). It is of 
particular interest to establish whether current definitions of metabolic health help identify 
lean individuals at high-risk of type 2 diabetes (i.e. the ‘metabolically unhealthy lean’) or 
obese individuals at low risk of type 2 diabetes (i.e. the ‘metabolically healthy obese’). 
  We therefore reviewed the literature on the definitions of metabolic health and assessed 
their relevance to the prediction of incident type 2 diabetes in lean, overweight or obese 
individuals.  
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Research Design and Methods  
Literature searches 
  This report adheres to the PRISMA guidelines, where applicable (11). We used three 
complementary strategies in order to assess the existing literature on the definitions of 
metabolic health in BMI categories. Firstly, we reviewed titles and abstracts of all references 
cited by Stefan et al. (4) and Kramer et al. (5) in recent reviews on the topic. Secondly, we 
reviewed titles and abstracts retrieved by a MEDLINE search from inception through to the 
1
st
 of September 2014 with the following terms (Search 1): ‘metabolically-healthy obesity OR 
metabolically-healthy obese OR metabolically healthy obesity OR metabolically healthy 
obese’. In order to maximise sensitivity for the detection of studies of incident type 2 
diabetes, we conducted a second MEDLINE search from 2000 to the 1
st
 of September 2014 
with the following strategy (Search 2): ‘(Diabetes Mellitus, Type 2[MeSH Terms] OR “type 2 
diabetes”[Title/abstract] OR “diabetes”[Title] OR Type II Diabetes Mellitus OR Type 2 
Diabetes Mellitus OR Noninsulin-Dependent Diabetes Mellitus OR Diabetes Mellitus, Type II 
OR Diabetes Mellitus, Type 2 NOT “type 1 diabetes”[Title/abstract]) AND (adiposity OR 
“body mass index”[MeSH Terms] OR body mass index[Text Word] OR “overweight”[MeSH 
Terms] OR overweight[Text Word] OR “obesity”[MeSH Terms] OR obesity[Text Word]) 
AND (metabolic health OR metabolically healthy OR metabolic status OR high risk OR risk 
category OR risk stratification OR cardiometabolic health OR cardiometabolic risk) AND 
(epidemiologic studies[MeSH Terms] OR epidemiologic study OR observational study OR 
case-control OR cross-sectional OR case-cohort OR longitudinal study OR cohort OR cohort 
study OR follow-up study OR cohort analysis OR incidence study) AND (humans[MeSH 
Terms]) AND ("2000"[Date - Publication] : "3000"[Date - Publication]) AND 
English[Language]’.  
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  Titles, abstracts and full articles were reviewed by one author (L.A.L.) with the 
following criteria. For title review, the title had to refer to the definition of metabolic health 
or cardio-metabolic risk stratification in lean, obese or overweight individuals. For abstract 
and full-article reviews, the following inclusion criteria were used: (a) the study had cross-
sectional, case-control, cohort, cohort-derived design (nested case-control or case-cohort); (b) 
the study provided an explicit definition of metabolic health in lean, overweight or obese 
individuals or used one or more variables to stratify cardiometabolic risk in these categories. 
Exclusion criteria were as follows: (a) the manuscript reported a randomised controlled trial, 
another intervention study (e.g. life-style interventions or studies on individuals who were 
candidate to bariatric surgery) or a review of the literature; (b) the study used obesity, BMI, 
or another anthropometric variable as the risk factor or as the outcome, rather than stratifying 
variable; (c) the study was restricted to metabolically healthy or unhealthy individuals only, 
was not conducted in adult humans, was a genetic association study, or was restricted to 
patients with diabetes or other cardio-metabolic disease. 
 One author (A.S.) was asked to independently review 10% of the records of each stage of 
each search. Inconsistencies were resolved by repeated review and discussion. Concordance 
was high (96% for titles, n = 256/269; 97% for abstracts, n = 68/70; 100% for articles, n = 
18/18). Data on definitions of metabolic health from all screened articles (n = 126) and full 
information from articles reporting on incident type 2 diabetes (n = 16) were extracted. 
Studies on incident type 2 diabetes were qualitatively assessed using a modified version of 
the scoring system proposed by Bell et al. in a recent review (6).  
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Definition of BMI and metabolic health categories in studies of incident type 2 diabetes 
 For studies in non-East Asians, BMI categories were defined as follows: lean < 25, 
overweight 25-29.9 and obese ≥ 30 kg/m
2 
(12). For East Asians, we used categories of BMI 
associated with ‘acceptable, increased and high’ risk of metabolic disease according to a 
recent communication of the World Health Organization, i.e. lean < 23, overweight 23-27.4 
and obese ≥ 27.5 kg/m
2 
(13). Where the authors did not use these cut-offs, we contacted them 
using a standardised electronic mail message and asked for a reclassification of the 
participants.   
  Metabolic health definitions, mainly consisting of insulin resistance and metabolic 
syndrome, were carried over from the original reports.  
  
Two-stage meta-analysis 
 Our meta-analysis was conducted in two stages. In the first stage, we used network meta-
analysis to derive, for each study, the relative risk (RR) of type 2 diabetes of metabolically 
unhealthy compared with healthy individuals in the lean, overweight and obese categories. In 
the second stage, we pooled the resulting RRs using random effects models 
 
Network meta-analysis 
  The primary objectives of this study were to (a) assess the risk of type 2 diabetes 
associated with current definitions of metabolic health within the lean, overweight and obese 
categories and (b) to assess the predictive relevance of these definitions. However, only one 
study (14) reported RR comparing unhealthy and healthy individuals within each BMI 
category. In all the other instances, articles reported the risk of all groups relative to the 
metabolically healthy lean (6,15-28). These comparisons may be of limited value when 
assessing the predictive relevance of metabolic health definitions. For instance, a comparison 
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of metabolically unhealthy obese vs metabolically healthy lean simultaneously evaluates the 
contribution of two risk factors (i.e. BMI and level of metabolic health).  
  In instances where there was a need to contact the authors for clarifications, we asked for 
additional analyses within BMI categories (see Supplementary Table S1). When there was no 
need to contact authors, we inferred the RR in the overweight and obese categories using 
network meta-analysis within each study (Supplementary Table S1 and Text). Network meta-
analysis is a meta-analysis approach allowing indirect comparison of evidence, which has 
previously been applied in the context of randomised controlled trials (29,30). Here, we used 
this method in order to estimate, for each study, the RR of metabolically unhealthy vs healthy 
individuals in the overweight and obese categories. To do this, we used the comparisons with 
the metabolically healthy lean category as input evidence (Supplementary Text).  
 
Meta-analysis of relative risk estimates 
  In the second stage of our meta-analysis, adjusted estimates of RR were pooled across 
studies using random effects models. Random effects models were used because of the 
heterogeneity in the definitions of metabolic health. Analyses were stratified by sex (i.e. 
studies with proportion of women ≤ 30% vs all other studies), age (i.e. mean or median age in 
the 3
rd
 or 4
th
 decade vs 5
th
 or 6
th
 decade), country or population (i.e. non-East Asian vs East 
Asian; European vs other non-East Asian vs East Asian), definition of metabolic health (i.e. 
metabolic syndrome vs insulin resistance), sample size (i.e. below vs above 5,000 
participants), length of follow-up (below vs above 7 years of mean or median follow-up) or 
extent of adjustment (i.e. crude or minimal vs extensive). Because three of the sixteen 
selected studies were conducted in the same source population with overlapping but not 
identical criteria of selection and follow-up periods, only the largest of these studies was 
included in the main analysis. Analyses with either of the other two studies, instead of the 
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largest, yielded comparable results (Supplementary Table S2). In studies using more than one 
definition, we arbitrarily chose one for inclusion in our main analysis. In doing so, we chose 
those analyses using metabolic syndrome as a criterion for the definition of metabolic health 
(i.e. in the instance of Meigs et al. (18) and Arnlöv et al. (19)) and those with more relaxed 
criteria for the definition of metabolic health (i.e. in the instance of Bell et al.(6)). Egger’s test 
and funnel plots were used to assess publication bias. The I-squared statistic was used to 
quantify heterogeneity. The source of heterogeneity was investigated by the aforementioned 
stratified analyses. 
 
Absolute type 2 diabetes risk estimation 
  The cumulative incidence of type 2 diabetes in metabolic health and BMI categories was 
estimated using a probabilistic analysis (20,000 simulations), which simultaneously 
incorporates the uncertainty in the estimates of each of the input parameters. Input parameters 
in the model were (a) the proportion of participants who were metabolically healthy within 
each of the three BMI categories in our meta-analysis of 140,845 participants; (b) the RR of 
type 2 diabetes within each BMI category as estimated by our random effects model meta-
analysis and (c) the cumulative incidence of type 2 diabetes at 5- and 10-years of follow-up 
from the EPIC InterAct case-cohort study (31).  
 
Predictive relevance 
  The predictive relevance of metabolic health definitions was studied by hierarchical 
summary receiver operating characteristic curves and Fagan’s nomograms. The meta-analysis 
of predictive test accuracy was performed by fitting a two-level mixed effects logistic 
regression model, with independent binomial distributions for the true positives and true 
negatives conditional on the sensitivity and specificity in each study, and a bivariate normal 
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model for the logit transforms of sensitivity and specificity between studies. Sensitivity and 
specificity were expressed as proportions and their use in this study pertains to the prediction 
of future disease in diabetes-free individuals. Fagan’s nomograms represent the predictive 
performance of a test with lines intercepting three parallel vertical axes. The leftmost axis 
indicates the pre-test probability of disease, the rightmost axis the post-test probability and 
the central axis the positive or negative likelihood ratio. Lines are then drawn from the pre-
test probability on the left through the likelihood ratio in the centre and extended to the 
posterior probabilities on the right to represent scenarios of a positive or negative test result 
in each of the three BMI categories. Likelihood ratios were used to evaluate contribution to 
prediction using cut-offs recommended by the authors of the fagan STATA package (32). 
 
Statistical analysis 
 Analyses were carried out using STATA v13.1 (StataCorp, College Station, Texas 77845 
USA). The network package was used for network meta-analysis (30), metan for random 
effects model meta-analysis (33), metandi (32) and fagan (URL: http://fmwww.bc.edu/repec/ 
/bocode/f/fagan.ado; author, Ben Dwamena, Division of Nuclear Medicine, Department  of 
Radiology, University of Michigan Health System, Ann Arbor, USA) for meta-analysis of 
predictive test accuracy (32). The probabilistic analysis for estimation of cumulative 
incidences was carried out using openBUGS (34). 
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Results 
Literature search 
 Figure 1 depicts the literature search workflow. A total of 3122 MEDLINE records were 
reviewed and 126 articles matching our search criteria were selected for data extraction. The 
articles reported a total of 177 analyses using a definition of metabolic heath. Definitions of 
metabolic health were mostly binary (i.e. healthy or unhealthy) and fell into five broad 
categories: (a) metabolic syndrome, (b) metabolic syndrome combined with insulin resistance 
or other criteria, (c) insulin resistance, (d) cardiorespiratory fitness, (e) miscellaneous. 
Metabolic syndrome defined according to the Adult Treatment Panel III criteria (35), insulin 
resistance according to the homeostatic model assessment
 
(36) and combined definitions 
provided by Wildman et al. (7) and Karelis et al. (8) were most frequently used. 
Supplementary Table S3 reports the breakdown of the 177 definitions into these five broad 
categories.  
 We identified a total of sixteen manuscripts reporting on cohort studies of incident type 2 
diabetes in BMI and metabolic health categories (Table 1) (6,14-28). Studies were mostly 
population-based cohort studies in middle-aged individuals with a mean or median follow-up 
ranging from 4 to 17.5 years. Qualitative assessment revealed generally high quality (Table 
1). In the main analysis, we retained only the largest (25) of three studies that investigated the 
same source population (16,25,28). A total of fourteen studies, comprising 140,845 
participants and 5963 incident cases, were included in the quantitative meta-analysis 
(6,14,15,17-27).  
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Network meta-analysis and random effects meta-analysis of relative risk estimates 
 In a meta-analysis of type 2 diabetes risk within BMI and metabolic health categories, all 
groups had higher risk when compared to the healthy lean group (RR [95% confidence 
interval, CI]: metabolically unhealthy lean group, 4.0 [3.0 – 5.1]; metabolically healthy 
overweight group, 1.8 [1.5 – 2.2]; metabolically unhealthy overweight group, 6.2 [ 4.8 – 8.0]; 
metabolically healthy obese group, 4.1 [3.3 – 5.1]; metabolically unhealthy obese group, 10.9 
[8.5 – 13.9]; see also Supplementary Table S4 and Figure S1). 
 Where analysis results were not available from the manuscript or from direct contact 
with the authors, network meta-analysis was used to derive within-overweight and within-
obese category RRs and 95% CI. In instances where both estimates were available, the 
central estimate of RR provided by the authors strongly correlated with that obtained by 
network meta-analysis (average r
2
 > 0.95; n = 18; see Supplementary Table S1). The relative 
risks obtained in this first stage were then pooled using random effects meta-analysis. 
Random effects meta-analysis revealed that – when compared with healthy individuals – 
metabolically unhealthy individuals are at higher risk of type 2 diabetes in all BMI categories 
(RR compared with healthy individuals [95%, CI]: lean, 4.0 [3.0 – 5.1], N at risk / type 2 diabetes = 
67,281 / 1,393; overweight, 3.4 [2.8 – 4.3], N at risk / type 2 diabetes = 58,060 / 2,903; obese, 2.5 
[2.1 – 3.0], N at risk / type 2 diabetes = 15,504 / 1,667; see Figure 2). The relative risk of type 2 
diabetes associated with being classified as unhealthy was highest in the lean category and 
lowest in the obese category. Funnel plots and Egger’s test (P > 0.1 for all comparisons) 
indicated no publication bias (Supplementary Figure S2). There was heterogeneity between 
studies in the estimated RR within the lean and overweight categories, but not the obese 
category (Figure 2). Stratified analyses revealed that ethnicity was likely the driver of 
heterogeneity, with RR higher in East Asian populations in all BMI categories (Figure 2). 
Further stratification for geographic region (European vs East Asian studies) resolved 
Page 11 of 67
CONFIDENTIAL-For Peer Review Only
Diabetes Care
12 
 
residual heterogeneity in estimates in the lean category (Supplementary Figure S3). Results 
were similar in studies using metabolic syndrome or insulin resistance as definitions for 
metabolic health. 
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Absolute type 2 diabetes risk estimation and predictive relevance 
 Using a probabilistic analysis, which simultaneously incorporates uncertainty in all the 
input parameter estimates, we estimated the cumulative incidence of type 2 diabetes at 5 and 
10 years in all BMI and metabolic health categories (Table 2). Metabolically healthy obese 
individuals had a cumulative incidence of type 2 diabetes over 10 years of 3.1% (95% CI: 2.6 
– 3.5%). Cumulative incidence estimates from a sensitivity analysis after exclusion of studies 
in East Asian populations were largely overlapping with those of the main analysis 
(Supplementary Table S5).  
 Hierarchical summary receiver operating curve analysis revealed increasing sensitivity 
and decreasing specificity in higher BMI categories (Figure 3A-C). In lean individuals, 
testing metabolic health was not sensitive (pooled estimate [95% CI]: 0.40 [0.31 – 0.49]), but 
was specific (0.88 [0.84 – 0.91]). In overweight individuals, both sensitivity (0.65 [0.56 – 
0.74]) and specificity (0.68 [0.61 – 0.74]) were low. In obese individuals, sensitivity was 
acceptable (0.81 [0.76 – 0.86]), but specificity (0.42 [0.35 – 0.49]) was low. The pooled 
estimates of the positive likelihood ratio were 3.3 (95% CI:  2.7 – 3.9) in lean category, 2.0 
(1.8 – 2.3) in the overweight category and 1.4 (1.3 – 1.5) in the obese category. The pooled 
estimates for the negative likelihood ratio were 0.7 (95% CI: 0.6 – 0.8) in the lean category, 
0.5 (0.4 – 0.6) in the overweight category and 0.5 (0.4 – 0.5) in the obese category. These 
likelihood ratios show that current binary definitions of metabolic health make only small or 
insignificant contributions to the prediction of future type 2 diabetes in BMI categories 
(Figure 3D-E). 
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Discussion 
 In this study, we reviewed definitions of metabolic health, which have been used to 
classify the risk of metabolic disease in BMI categories. We also sought to assess the risk of 
type 2 diabetes associated with being classified as metabolically unhealthy in lean, 
overweight and obese individuals. We found that being classified as metabolically unhealthy 
is associated with higher risk of type 2 diabetes relative to the healthy group in all categories 
of BMI.  
 Our study is the largest meta-analysis of the risk of type 2 diabetes associated with 
metabolic health definitions and the only one to have assessed risk within BMI categories. In 
a meta-analysis by Bell et al. (6) of eight studies, with a total of 27,982 participants, relative 
risk was calculated using the healthy lean category as a reference. This is not informative 
about the risk of type 2 diabetes within BMI categories or the predictive relevance of 
metabolic health definitions. In this study, we obtained within BMI-category risk estimates 
using network meta-analysis, a method for the pooling of indirect evidence used in meta-
analyses of randomised controlled trials. The method accurately estimated the relative risk in 
BMI categories, with a loss of precision, due to the uncertainty of indirect estimations, which 
was offset by the large overall sample size of this meta-analysis. Using this method, we were 
able to show that the relative risk of type 2 diabetes is higher in all categories of BMI for 
metabolically unhealthy individuals compared with those who are classified as metabolically 
healthy. Relative risks within the lean and overweight categories were higher in East Asian 
populations. This probably reflects the higher prevalence of abdominal obesity and insulin 
resistance in these populations compared with Europeans at a given level of BMI (37, 38). 
 However, relative risk only partially accounts for the predictive relevance of a given 
definition. Predictive relevance has to be evaluated also in the context of absolute risk. The 
absolute risk of individuals deemed to be ‘metabolically healthy obese’ was high, with an 
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estimated cumulative incidence of type 2 diabetes over 10 years exceeding 3%. This raises 
doubts about the predictive value of currently used binary definitions of metabolic health. An 
analysis of hierarchical summary receiver operating characteristics curve and Fagan’s 
nomograms revealed limited predictive relevance in all three BMI categories.  
 Metabolic health definitions had a predictive performance opposite of the desirable, with 
low sensitivity in the lean category and low specificity in the obese category. In the lean 
category, metabolic health definitions had high specificity and could therefore be considered 
as a confirmatory test. However, there is presently no screening test to identify at-risk lean 
individuals in the population. With an absolute risk of 2.2% at 10 years, one would argue that 
metabolically unhealthy lean individuals would not be candidates for particular preventive 
measures besides those recommended for the general population. In overweight individuals, 
current binary definitions of metabolic health had low sensitivity and specificity. The 
metabolically healthy overweight individuals had an absolute risk of type 2 diabetes greater 
than that of the lean category and the metabolically unhealthy overweight individuals an 
absolute risk smaller than that of the obese category. In addition, the metabolically unhealthy 
overweight group accounted for 40% of the overweight category, which is in many countries 
the largest BMI category in the general population. Therefore, it is difficult to conceive 
preventive measures that could efficiently target such a large portion of the population. In 
obese individuals, using current metabolic health definitions may be sensitive. However, 
specificity in this group was well below acceptable levels and ‘metabolically healthy’ obese 
individuals still had an absolute risk greater than that of the overweight category.  
 In addition to these limitations, defining metabolic health entails invasive biological 
sampling for the measurement of biomarkers such as glucose, triglycerides, high-density 
lipoprotein cholesterol or insulin. In particular, the criteria for some of the definitions of 
metabolic health include fasting glucose, which is a major predictor of type 2 diabetes (39). 
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Therefore, the value of using any of the other criteria (e.g. high-density lipoprotein 
cholesterol or triglycerides) included in these definitions in addition to fasting glucose is 
likely to be limited. Overall, there is little support for use of these definitions for the 
prediction or classification of type 2 diabetes risk in BMI categories. These considerations 
apply to currently-used binary definitions of metabolic health. It is possible that more 
comprehensive approaches to the definition of metabolic health may yield better predictive 
performance. Also, our meta-analytic approach pooled evidence from studies using different 
definitions of metabolic health. However, our analytical approach accounted for possible 
differences in the performance of definitions of metabolic health used in the constituent 
studies of the meta-analysis.   
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Conclusions 
  In conclusion, in a meta-analysis of 140,845 participants, being classified as 
metabolically unhealthy as compared with healthy using current binary definitions of 
metabolic health was associated with higher relative risk of type 2 diabetes in all BMI 
categories. However, when considering predictive performance in the context of absolute 
risk, we found that current binary definitions of metabolic health have limited predictive 
relevance. Our study does not support the use of current definitions of metabolic health for 
the prediction or classification of type 2 diabetes risk.  
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Figure Legends 
Figure 1. Workflow of the review. MHO indicates metabolically healthy obesity; a, Search 2 as described in 
the Methods section; b, Search 1, as described in the methods section; c, article restricted to unhealthy lean or 
used BMI as the endpoint/only risk factor rather than stratifying variable. 
Figure 2. Relative risk of type 2 diabetes in metabolically unhealthy compared with healthy individuals by 
body mass index category and country (non-East Asian or East Asian). 
Figure 3. Performance of metabolic health definitions in the prediction of future development of type 2 
diabetes. The top Panels report hierarchical summary receiver operating characteristic (HSROC) curves of the 
predictive performance in lean (Panel A), overweight (Panel B) and obese (Panel C) individuals. Solid squares 
represent pooled estimates; open circles, individual study estimates with a size that is proportional to the weight 
of each study; solid lines, HSROC curves; broken lines delimit uncertainty in the estimates of the summary 
points (95% confidence region) or of the HSROC curves (95% prediction region). In Panels D and E, Fagan’s 
nomograms represent scenarios of positive (i.e. metabolically unhealthy; Panel D) or negative (i.e. metabolically 
healthy individual; Panel E) results of the binary classification of metabolic health in body mass index 
categories.  
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Tables 
 
Table 1. Cohort studies investigating incident type 2 diabetes in metabolic health and body mass index categories. 
First Author 
Year; 
Pubmed ID 
Country /  
years of 
recruitment 
Definition of metabolic healtha 
Definition of 
BMI 
categories, in 
kg/m2 
Study population 
Sample size 
and incident 
cases 
(Ntotal/NT2D) 
Incident T2D 
ascertainment 
Length of 
follow-up 
Adjustment 
Quality 
scoreb 
Meigs 
2006; 
16735483 
Framingham 
Offspring 
Study, 
USA 
1991-1995 
 
(1) MetS, 3 / 5 ATPIII criteria: FG < 
5.6, WC ≤ 88 102 M or 88 W, TG < 
1.7, HDL ≥ 1 M or 1.3 W, BP < 
130/85 
 
(2) IR: HOMA-IR ≤ 75th percentile 
of distribution in subjects without 
T2D 
 
Lean < 25  
OW 25-29.9  
Obese ≥ 30 
 
Offspring of community-based 
study; European ancestry; free 
from CVD and T2D at 
baseline; mean age, 54 years; 
women, 55% 
 
(1) 2902 / 141 
(2) 2803 / 135 
FG ≥ 7.0 mmol/L or 
new use of 
hypoglycaemic 
therapy 
Mean 6.8 
years 
Age, sex, family history 
of diabetes, and impaired 
glucose tolerance 
6 
Arnlöv 
2011; 
20852030 
Uppsala 
Longitudinal 
Study of Adult 
Men, 
Sweden 
1970-1973 
 
(1) MetS: 3 / 5 ATPIII criteria: FG 
< 6.1c, BMI ≥  29.4d,TG < 1.7, 
HDL ≥ 1.04, BP < 130/85 
 
(2) IR: HOMA-IR ≤ 75th 
percentile of distribution in 
subjects without T2D, i.e. 3.43 
 
Lean < 25 OW 
25-30  
Obese > 30 
Community-based study of 
men born in 1920-1924 free 
from T2D at baseline; mean 
age, 50 years, women, 0% 
(1) 1675 / 160 
(2) 1385 / 117 
FG ≥ 7.0 mmol/L at 
follow-up or data from 
national hospital-
discharge registry 
Up to 20 
years 
Age, smoking status, and 
level of physical activity 
6 
Hadaegh 
2011; 
21609497 
 
Tehran Lipid 
and Glucose 
Study, 
Iran 
1999-2001 
 
MetS: 3 / 5 harmonised criteria: FG 
< 5.5, WC < 94.5, TG < 1.7, HDL ≥ 
1.04 M or 1.3 W, BP < 130/85 
Lean < 25  
OW 25-29.9  
Obese ≥ 30 
Population based cohort study 
in Tehran; mean age, 42 years;  
women, 58% 
5,250 / 369 
Self-reported or 
OGTT-based at two 
follow-up visits 
Median 6.5 
years 
Age, family history of 
T2D, history of CVD, 
education, smoking 
status 
6 
Kim 
2012; 
22621338 
South Korea 
2005 
MetS: 3 / 5 2009 
harmonised criteria: FG < 5.6, WC < 
90 M or 80 W, TG < 1.7, HDL ≥ 1 
M or 1.3 W, BP < 130/85 
Lean < 23  
OW 23-27.4  
Obese ≥ 27.5 
 
Subjects attending baseline and 
follow-up visits at Health 
Promotion Centre; mean age, 
48 years; women, 35% 
 
8,748 / 308 
FG ≥ 7.0 mmol/L or 
HbA1c ≥ 6.5% or 
treatment 
5 years 
Age, sex, smoking, 
alcohol consumption, 
and physical activity 
6 
Bo 
2012; 
23034958 
Italy 
2001-2003 
MetS plus IR: 3 / 5 harmonised 
criteria: FG < 5.6, WC < 94 M or 80 
W, TG < 1.7, HDL ≥ 1 M or 1.3 W, 
BP < 130/85 
AND 
HOMA-IR < 2.5 
Lean < 25  
OW 25-30  
Obese > 30 
Caucasian volunteers from 
Local Health Units; mean age, 
54 years; women, 53% 
1,658 / 72 
Self-reported, FG, 
demographic registries 
9 years Nonee 6 
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Table 1. (Continued I) 
 
First Author 
Year; 
Pubmed ID 
Country /  
years of 
recruitment 
Definition of metabolic healtha 
Definition of 
BMI categories, 
in kg/m2 
Study population 
Sample size 
and incident 
cases 
(Ntotal/NT2D) 
Incident T2D 
ascertainment 
Length of 
follow-up 
Adjustment 
Quality 
scoreb 
Appleton 
2013; 
23491523 
 
North West 
Adelaide Health 
Study, 
Australia 
1999-2003 
 
MetS: 3 / 4 IDF criteria: FG < 5.6, 
TG < 1.7, HDL ≥ 1 M or 1.3 W, BP 
< 130/85 
Lean 18.5-24.9 
OW 25-29.9  
Obese ≥ 30 
Community-based study; 
Adults of European ancestry; 
free from T2D and CVD at 
baseline; mean age,  42 
yearsf; womenf, 57% 
2315 / 112 
Self-reported doctor 
diagnosis or FG ≥ 7.0 
mmol/L 
Median 8.2 
years 
Age, sex, 
household income, and 
family history of 
diabetes 
6 
Soriguer 
2013; 
23559087 
 
Prospective 
Pizarra Study, 
Spain  
1997-1998 
 
 
MetS plus IR: 3 / 3 criteria: FG < 
6.1, TG < 1.7, HOMA-IR < 90th 
percentileg 
 
Lean < 25  
OW 25-29.9  
Obese ≥ 30 
Population-based cohort 
study; mean age, 40 years; 
women, 62%h 
387 / 38e 
Self-reported or FG at 
follow-up 
11 years Age, sexe 5 
Aung 
2014; 
24257907 
San Antonio 
Heart Study, 
USA 
1979-1988 
 
MetS plus IR: 4 / 5 criteria: FG < 
5.6, TG < 1.7, HDL ≥ 1 M or 1.3 W, 
BP < 130/85, HOMA-IR ≤ 5.13 
  
Lean < 25  
OW 25-29.9  
Obese ≥ 30 
 
Population based cohort 
study of Mexican and 
Caucasian Americans; mean 
age, 42 years; women, 57% 
 
2,814 / 262 
OGTT or medication 
at follow-up 
Median 7.4 
years 
Age, sex, ethnicity, 
family history of 
diabetes, fasting glucose 
6 
Sung 
2012; 
24361070 
South Korea 
2003 
IR: HOMA-IR < 2, i.e. 75th 
percentile 
Lean < 23  
OW 23-27.49  
Obese ≥ 27.5e 
Participants of health 
examination at hospital; 
mean age, 41 years; women, 
29% 
12,853 / 223 
Self-reported, medical 
history or FG at 
follow-up 
5 years 
 
Age, sex, alcohol, 
smoking status, exercise, 
educational status, 
baseline glucosee 
 
5 
Bell 
2014; 
24661566 
English 
Longitudinal 
Study of 
Ageing, 
UK 
2004-2005 
 
(1) MetS plus CRP: 3 / 5 
customised criteria: Hba1c < 
6%, TG < 1.7, HDL ≥ 1 M or 
1.3, BP < 130/85, CRP < 0.3 
mg/dL 
 
(2) MetS plus CRP: 4 / 5 of the 
criteria used in definition (1) 
 
Lean < 25  
OW 25-29.9  
Obese ≥ 30 
Population-based cohort 
study; mean age, 65 years; 
women, 57% 
3,060 / 138 
Self-reported 
physician diagnosis 
Mean 5.9 
years 
 
Age, sex, smoking, 
alcohol intake, physical 
activity, wealth, 
depressive symptoms 
 
5 
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Table 1. (Continued II) 
 
First 
Author 
Year; 
Pubmed ID 
Country /  
years of 
recruitment 
Definition of metabolic 
health
a
 
Definition of 
BMI 
categories, in 
kg/m2 
Study population 
Sample size 
and incident 
cases 
(Ntotal/NT2D) 
Incident T2D 
ascertainment 
Length of 
follow-up 
Adjustment 
Quality 
scoreb 
Hinnouho 
2014; 
24670711 
Whitehall II 
Study, 
UK 
1991-1993 
MetS: 3 / 4 ATPIII criteria: FG < 
5.6, TG < 1.7, HDL ≥ 1.04 M or 
1.29 W, BP < 130/85 
Lean 18.5-24.9  
OW 25-29.9  
Obese ≥ 30 
Cohort study of office 
workers in central London; 
mean age, 49 years; 
women, 30% 
7,122 / 798 
OGTT, physician 
diagnosis or use of 
medication at follow-
up 
Median 17.5 
years 
 
Sex, socioeconomic 
status, marital status, 
ethnicity, physical 
activity, smoking, 
alcohol, fruits and 
vegetables consumption, 
CVD medications and 
procedures 
 
6 
Heianza 
2014 
J Clin 
Endocrinol 
Metab; 
24823457 
 
Toranomon 
Hospital Health 
Management 
Centre Study, 
Japan 
1997-2002 
 
MetS: 3 / 4 IDF criteria: FG < 5.6, 
TG < 1.7, HDL ≥ 1.03 M or 1.29 
W, BP < 130/85 
Lean < 23  
OW 23-27.4  
Obese ≥ 27.5e 
 
Cohort Study of Japanese 
government employees; 
mean age, 48 years; 
women, 27% 
 
8,090 / 274e 
FG ≥ 7, Hba1c ≥ 
6.5%, or self-reported 
5 years 
Age, sex, smoking, 
physical activity, alcohol 
intake, family history of 
diabetese 
6 
Rhee  
2014; 
24870949 
South Korea 
2005 
MetS plus IR: 3 / 4 criteria: FG < 
5.6, TG < 1.7, HDL ≥ 1 M or 1.3 
W, BP < 130/85 AND  
HOMA-IR < 90th percentile  
Lean < 23  
OW 23-27.4  
Obese ≥ 27.5e 
 
Participants of medical 
check-up programme; 
mean age, 43 years; 
women, 27% 
 
6,748 / 277 
FG, Hba1c or self-
reported history or 
medication 
4 years 
 
Age, sex, ALT, 
creatinine, total 
cholesterol, hs-CRPe 
 
6 
Heianza 
2014 
Obesity; 
25131796 
Japan 
1999-2004 
MetS: 3 / 4 IDF criteria: FG < 5.6, 
TG < 1.7, HDL ≥ 1.03 M or 1.29 
W, BP < 130/85 
Lean < 23  
OW 23-27.4  
Obese ≥ 27.5e 
 
Cohort Study of 
individuals occupational 
health examinations; mean 
age, 47 years; women, 36% 
 
27,891 / 1,668e 
FG ≥ 7, Hba1c ≥ 
6.5%, or self-reported 
8 years 
Age, sex, smoking, 
physical activitye 
6 
Twig 
2014; 
25139886 
Metabolic, 
Lifestyle and 
Nutrition 
Assessment in 
Young Adults, 
Israel 
1995-2011 
MetS: 3 / 4 ATPIII criteria: FG < 
5.6, TG < 1.7, HDL ≥ 1, BP < 
130/85 e,i 
Lean < 25  
OW 25-29.9  
Obese ≥ 30 
Cohort study of men from 
the Israel Defence Forces; 
mean age, 31 years; 
women, 0% 
33,939 / 734 
FG or physician 
diagnosis 
Median 6.1 
years 
Age, family history of 
diabetes, country of 
origin, WBCe 
6 
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Table 1. (Continued III) 
 
First 
Author 
Year; 
Pubmed ID 
Country /  
years of 
recruitment 
Definition of metabolic 
health
a
 
Definition of 
BMI categories, 
in kg/m2 
Study population 
Sample size 
and incident 
cases 
(Ntotal/NT2D) 
Incident T2D 
ascertainment 
Length of 
follow-up 
Adjustment 
Quality 
scoreb 
Jung 
2014; 
25155902 
South Korea 
2005-2006 
MetS: 4 / 4 IDF criteria: FG < 5.6, 
TG < 1.7, HDL ≥ 1 M or 1.3 W, BP 
< 130/85 
Lean < 23  
OW 23-27.4  
Obese ≥ 27.5e 
 
Cohort study of employees 
of large Korean company 
and their spouses; mean 
age, 37 years; women, 44% 
 
34,994 / 889e 
FG ≥ 7, Hba1c ≥ 
6.5% or medication 
5 years 
Age, sex, smoking, 
alcohol intake, physical 
activitye 
6 
  
Abbreviations: BMI, body mass index; T2D, type 2 diabetes; MetS, metabolic syndrome; IR, insulin resistance; HOMA-IR, Homeostatic model assessment – insulin resistance; ATPIII, Adult Treatment Panel III; FG, fasting glucose; TG, 
triglycerides; HDL, high-density lipoprotein cholesterol; BP, blood pressure; WC, waist circumference; M, men; W, women; OW, overweight; OGTT, oral glucose tolerance test; WBC, white blood cells; IDF, International Diabetes Federation; 
CVD, cardiovascular disease; hs-CRP, high-sensitivity C-reactive protein. 
Notes: a All cut-off values expressed as cm for waist circumference, mmol/L for fasting glucose, HDL cholesterol or triglycerides, kg/m2 for BMI and mmHg for blood pressure. In some studies treatment with medication (e.g. anti-hypertensive 
drugs) was used as a complementary factor to adjudicate metabolic risk criteria. b We used a quality score similar to the one reported by Bell et al. Study quality was assessed according to the definition of exposure, outcome and to the extent of 
adjustment. Points were assigned as follows: 2 points if the study considered metabolic risk factor clustering as in the metabolic syndrome; 1 point if the study considered insulin resistance only; 2 points if diabetes diagnosis was based on 
objective clinical measurements (e.g. fasting or two hour glucose levels); 1 point if diabetes adjudication was based on self-report only; 2 points for extensive adjustment, i.e. age, sex plus at least two of the following, family history of diabetes, 
ethnicity, alcohol consumption, smoking status, physical activity, dietary habits and socioeconomic status, impaired glucose tolerance status; 1 point for basic adjustment, i.e. age and sex; 0 points for crude estimates. Studies were scored out of 
6 possible points. Adjustment in the original report was used to adjudicate the extent of adjustment. c Of fasting blood glucose, corresponding to fasting plasma glucose of 5.6 mmol/L. d BMI used in lieu of waist circumference criterion. e 
Information as reported by the authors in a personal communication. f Average of metabolically healthy lean, metabolically healthy obese, metabolically unhealthy obese groups. g The authors reported 4 different definitions of metabolic health. 
Here we report the one we used in the meta-analysis, for which the authors provided detailed results of type 2 diabetes incidence in a personal communication. h In the full baseline study. i In the original report metabolic health was the absence 
of any metabolic syndrome criteria and the risk of type 2 diabetes was evaluated for individuals with 1, 2, 3 or more criteria separately
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Table 2. Cumulative incidence of type 2 diabetes in metabolic health and body mass index categories. 
 
BMI category 
BMI category 
cumulative 
incidence at 5 
yearsa 
BMI category 
cumulative 
incidence at 10 
years a 
 
Risk category 
 
Proportion 
of healthy 
or 
unhealthy 
individuals 
in each 
BMI 
category 
Relative 
risk 
within 
BMI 
category 
Risk category 5 year 
cumulative incidence 
(95% CI*) 
Risk category 10 year 
cumulative incidence 
(95% CI*) 
Lean 0.3 % 0.8 % 
Metabolically 
Healthy 
Lean 
0.82 1 
0.2% 
(0.1 – 0.2%) 
0.5% 
(0.5 – 0.6%) 
Metabolically 
Unhealthy 
Lean 
0.18 4.0 
0.6% 
(0.6 – 0.8%) 
2.2% 
(1.9 – 2.5%) 
Over 
weight 
0.8 % 2.7 % 
Metabolically 
Healthy 
Overweight 
0.59 1 
0.4% 
(0.3 – 0.5%) 
1.3% 
(1.1 – 1.6%) 
Metabolically 
Unhealthy 
Overweight 
0.41 3.4 
1.4% 
(1.3 – 1.5%) 
4.5% 
(4.2 – 4.9%) 
Obese 1.8 % 5.9 % 
Metabolically 
Healthy 
Obese 
0.38 1 
1.0% 
(0.8 – 1.1%) 
3.1% 
(2.6 – 3.5%) 
Metabolically 
Unhealthy 
Obese 
0.62 2.5 
2.4% 
(2.2 – 2.5%) 
7.6% 
(7.3 – 8.0%) 
BMI, body mass index; CI, confidence interval. 
a From the EPIC InterAct Study 
*derived via a probabilistic analysis, which simultaneously incorporates the uncertainty in each of the parameter estimate (openBUGS, 
20000 simulations) 
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119
Unique abstracts 
from 
Stefan et al. and 
Kramer et al.
260
Abstracts selected 
from Search 1
2681
Titles identified with 
Search 1a
322
Abstracts from 
Search 2b
2421 Excluded
Not relevant
181 Excluded
Not relevant
49
Full manuscripts 
selected
24
Full manuscripts 
selected
141
Full manuscripts 
selected
183
Unique manuscripts 
after exclusion of 
duplicates
70 Excluded
Not relevant
236 Excluded
Not relevant
57 Excluded
29 study type not suitable
10 no MHO definition
4 obesity not consideredc
14 other criteria
126
Full manuscripts 
providing definitions 
of MHO
T2D-specific 
search
Endpoint-agnostic 
search
Recent review 
articles
Figure 1
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Supplementary Text. Network meta-analysis. 
 
Network meta-analysis is a technique used in meta-analysis of randomised controlled trials to leverage indirect 
evidence. With this method, evidence from comparisons between exposures A vs B and B vs C may be used to 
estimate the comparison A vs C. In this manuscript, we used network meta-analysis to estimate relative risks 
comparing metabolically healthy vs unhealthy individuals within BMI categories, as shown in the Figure.  
 
Inset Figure. Network meta-analysis approach to estimate within-stratum relative risk. MHL, metabolically 
healthy lean; MUL, metabolically unhealthy lean; MHOW, metabolically healthy overweight; MUOW, 
metabolically unhealthy overweight; MHO, metabolically healthy obese; MUO, metabolically unhealthy obese. 
 
 
 
 
Results obtained from network meta-analysis had very similar central estimates to the ones obtained from 
publications (n = 1, i.e. Hinnouho et al.) or from the authors (n = 8; see also Supplementary Table S1). The 
widths of confidence intervals were larger for network meta-analysis based estimates compared with those 
obtained by direct analysis. 
  
Study Analysis Reference Comparison OR 95% CI
Meigs 2006 1 MHL MHOW 1.3 0.9 – 1.9
Meigs 2006 2 MHL MUOW 2.1 1.4 – 3.2
Meigs 2006 NMA MHOW MUOW 1.6 0.9 – 2.8
Network meta-analysis
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Supplementary Table S1. Comparison of estimates obtained from authors versus those obtained by network 
meta-analysis. 
 
PMID Study 
T2D risk in 
overweight 
obtained from 
authors, RR (95% 
CI) 
T2D risk in 
overweight 
obtained by NMA, 
RR (95% CI) 
T2D risk in 
obese obtained 
from authors, RR 
(95% CI) 
T2D risk in 
obese obtained by 
NMA, RR (95% 
CI) 
23034958 Bo 2012 
3.5 
(1.4 – 8.7) * 
3.5 
(0.4 – 31.4) 
2.0 
(0.7 – 5.9) * 
2.0 
(0.2 – 18.9) 
24361070 Sung 2012 
1.9 
(1.3 – 2.9) * 
1.9 
(0.8 – 4.5) 
2.9 
(1.4 – 5.9) * 
2.8 
(0.9 – 8.3) 
23559087 Soriguer 2013 
6.1 
(1.4 – 27.4) * 
5.6 
(0.6 – 51.8) 
3.0 
(1.1 – 8.4) * 
2.5 
(0.3 – 18.3) 
24670711 Hinnouho 2014 
2.6 
(2.1 – 3.2) * 
2.5 
(1.8 – 3.4) 
2.0 
(1.4 – 2.8) * 
2.1 
(1.4 – 3.3) 
25139886 Twig 2014 
2.2 
(1.7 – 2.7) * 
2.2 
(1.5 – 3.0) 
2.1 
(1.6 – 2.7) * 
2.1 
(1.4 – 3.0) 
25155902 Jung 2014 
5.5 
(4.0 – 7.5) * 
5.5 
 (3.2 – 9.4) 
2.9 
(1.8 – 4.9) * 
2.9 
(1.5 – 5.7) 
25131796 Heianza 2014 
4.0 
(3.5 – 4.6) * 
3.9 
(3.0 – 5.0) 
3.1 
(2.3 – 4.0) * 
3.0 
(2.1 – 4.2) 
24823457 Heianza 2014 
4.3 
(2.8 – 6.5) * 
4.3 
(2.3 – 8.0) 
2.2 
(1.0 – 4.8) * 
2.1 
(0.9 – 5.2) 
24870949 Rhee 2013 
5.2 
(3.3 – 8.4) * 
5.2 
(2.2 – 12.7) 
3.4  
(1.5 – 8.1) * 
3.4 
(1.1 – 10.8) 
16735483 Meigs 2006 Not available 
6.1 
(2.1 – 17.4) * 
Not available 
4.7 
(1.5 – 14.7) * 
20852030 Arnlöv 2011 Not available 
2.2 
(1.1 – 4.5) * 
Not available 
0.9 
(0.3 – 2.6) * 
23491523 Appleton 2013 Not available 
5.1 
(1.5 – 17.0) * 
Not available 
3.7 
(1.2 – 11.6) * 
22621338 Kim 2012 Not available 
3.8 
(2.1 – 7.0) * 
Not available 
3.9 
(1.8 – 8.4) * 
21609497 Hadaegh 2011 men Not available 
2.1 
(1.0 – 4.7) * 
Not available 
1.6 
(0.6 – 4.5) * 
21609497 
Hadaegh 2011 
women 
Not available 
3.3 
(1.3 – 8.4) * 
Not available 
5.7 
(2.1 – 15.5) * 
24661566 Bell 2014 Not available 
5.8 
(1.0 – 32.7) * 
Not available 
2.7 
(0.5 – 15.4) * 
24257907 Aung 2014 Not available 
3.2 
(1.4 – 7.4) * 
Not available 
2.8 
(1.2 – 6.7) * 
PMID, Pubmed identity; T2D, type 2 diabetes; RR, relative risk; CI, confidence interval; NMA, network meta-analysis. 
*used for the main analysis 
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Supplementary Table S2. Main analysis results when the studies of Sung et al. or Rhee et al. were included in 
the meta-analysis instead of those of Jung et al. 
  
Analysis 
Reference 
Group 
Individuals at risk 
/ incident T2D, 
N / N 
Comparison 
Group 
Individuals at 
risk / incident 
T2D, 
N / N 
RRT2D  
(95% CI) 
P-value I-squared % 
Sung et al. 
included 
Metabolically 
Healthy 
Lean 
46,320 / 753 
Metabolically 
Unhealthy 
Lean 
7,479 / 533 
3.9 
(2.9 – 5.2) 
< 0.001 69.4 
Sung et al. 
included 
Metabolically 
Healthy 
Overweight 
29,866 / 925 
Metabolically 
Unhealthy 
Overweight 
16,060 / 1,650 
3.1 
(2.5 – 3.8) 
< 0.001 63.4 
Sung et al. 
included 
Metabolically 
Healthy 
Obese 
5,395 / 323 
Metabolically 
Unhealthy 
Obese 
7,479 / 1,167 
2.5 
(2.1 – 3.0) 
< 0.001 11.6 
Rhee et al. 
included 
Metabolically 
Healthy 
Lean 
48,668 / 752 
Metabolically 
Unhealthy 
Lean 
7,521 / 520 
4.1 
(3.1 – 5.4) 
< 0.001 69.5 
Rhee et al. 
included 
Metabolically 
Healthy 
Overweight 
32,937 / 950 
Metabolically 
Unhealthy 
Overweight 
16,058 / 1,586 
3.4 
(2.7 – 4.1) 
< 0.001 61.0 
Rhee et al. 
included 
Metabolically 
Healthy 
Obese 
5,799 / 327 
Metabolically 
Unhealthy 
Obese 
7,721 / 1,162 
2.5 
(2.1 – 3.0) 
< 0.001 13.9 
T2D, type 2 diabetes; RR, relative risk; CI, confidence interval. 
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Supplementary Table S3. Definitions of metabolic health. The Table reports definitions used in the studies 
selected for full article review. In parentheses the number of studies using a given definition is reported. 
 
Definition Category (n = 177) 
 
• Metabolic syndrome (n = 72) 
o Adult Treatment Panel III criteria  
o Customised or modified criteria 
o International Diabetes Federation 
o Harmonised criteria 
 
• Combination of metabolic syndrome with insulin resistance or other (n = 54) 
o Metabolic syndrome and insulin resistance 
o Metabolic syndrome, insulin resistance and C-reactive protein 
o Metabolic syndrome and C-reactive protein 
o Metabolic syndrome and medical history 
o Other 
 
• Insulin resistance (n = 37) 
o Homeostatic model assessment – insulin resistance 
o Hyperinsulinaemic euglycaemic clamp 
o Other 
 
• Cardiorespiratory fitness (n = 4) 
 
• Miscellaneous (n = 10) 
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Supplementary Table S4. Relative risk of type 2 diabetes in different metabolic health and BMI categories 
compared with the metabolically healthy lean category. 
 
Study 
Metabolically 
Healthy 
Lean, 
RR (95% CI) 
Metabolically 
Unhealthy 
Lean, 
RR (95% CI) 
Metabolically 
Healthy 
Overweight, 
RR (95% CI) 
Metabolically 
Unhealthy 
Overweight, 
RR (95% CI) 
Metabolically 
Healthy 
Obese, 
RR (95% CI) 
Metabolically 
Unhealthy 
Obese, 
RR (95% CI) 
2006 Meigs 
J Clin Endocrinol 
Metab 
Referent 
4.0 
( 1.4 – 11.6 ) 
1.1 
( 0.5 – 2.4 ) 
6.8 
( 3.4 – 13.4 ) 
2.2 
( 0.9 – 5.6 ) 
10.3 
( 5.4 – 19.5 ) 
2011 Arnlöv 
Diabetes Care 
 
Referent 
 
3.3 
( 1.4 – 7.8 ) 
3.5 
( 2.3 – 5.4 ) 
7.8 
( 4.4 – 13.6 ) 
11.7 
( 4.9 – 28.2 ) 
10.1 
( 5.2 – 19.5 ) 
2013 Appleton 
Diabetes Care 
 
Referent 
 
2.3 
( 0.7 – 7.5 ) 
0.9 
( 0.4 – 2.2 ) 
4.5 
( 2.1 – 9.7 ) 
2.1 
( 0.9 – 5.0 ) 
7.8 
( 3.8 – 16.0 ) 
2012 Kim 
Metab Syndr Relat 
Disord 
Referent 
7.3 
( 3.4 – 15.9 ) 
2.6 
( 1.7– 4.0 ) 
10.1 
( 6.5 – 15.7 ) 
4.3 
( 2.4 – 7.9 ) 
16.7 
( 10.4 – 26.8 ) 
2011 Hadaegh 
BMC Public Health – 
Men 
Referent 
3.1 
( 1.3 – 7.0 ) 
1.6 
( 0.9 – 2.9 ) 
3.4 
( 2.0 – 5.8 ) 
3.6 
( 1.5 – 8.4 ) 
5.7 
( 3.3 – 9.9 ) 
2011 Hadaegh 
BMC Public Health – 
Women 
Referent 
8.8 
( 3.7 – 21.2 ) 
2.3 
( 1.2 – 4.3 ) 
7.7 
( 4.0 – 14.9 ) 
2.2 
( 1.0 – 4.7 ) 
12.6 
( 6.9 – 23.2 ) 
2012 Bo 
Am J Clin Nutr 
 
Referent 
 
16.7 
( 3.5 – 79.7 ) 
5.7 
( 1.1 – 28.5 ) 
20.0 
( 4.7 – 85.0 ) 
15.8 
( 2.8 – 88.3 ) 
31.4 
( 7.4 – 133.6 ) 
2013 Soriguer 
J Clin Endocrinol 
Metab 
Referent 
5.2 
( 0.8 – 34.9 ) 
0.7 
 ( 0.1 – 3.6 ) 
3.9 
( 0.9 – 17.0 ) 
3.0 
( 0.7 – 12.4 ) 
7.3 
( 1.8 – 29.2 ) 
2014 Bell 
Obes Rev 
 
Referent 
 
9.9 
( 2.9 – 36.7 ) 
2.9 
( 0.8 – 10.3 ) 
16.7 
( 5.2 – 54.2 ) 
8.6 
( 2.4 – 30.4 ) 
23.5 
( 7.3 – 75.6 ) 
2014 Hinnouho 
Eur Heart J 
 
Referent 
 
3.2 
( 2.5 – 4.1 ) 
1.6 
( 1.2 – 2.0 ) 
3.9 
( 3.2 – 4.8 ) 
3.2 
( 2.3 – 4.5 ) 
6.9 
( 5.4 – 8.8 ) 
2014 Aung 
J Clin Endocrinol 
Metab 
Referent 
2.5 
( 1.1 – 5.6 ) 
1.8 
( 1.0 – 3.4 ) 
5.8 
( 3.2 – 10.4 ) 
3.9 
( 2.0 – 7.4 ) 
10.9 
( 6.2 – 19.2 ) 
2014 Twig Diabetes 
Care 
 
Referent 
 
1.7 
( 1.2 – 2.4 ) 
1.5 
( 1.2 – 2.0 ) 
3.3 
( 2.6 – 4.2 ) 
3.2 
( 2.4 – 4.4 ) 
6.7 
( 5.3 – 8.5 ) 
2014 Jung 
Obesity 
 
Referent 
 
3.8 
( 2.7 – 5.4 ) 
1.6 
( 1.0 – 2.4 ) 
8.6 
( 6.3 – 11.8 ) 
6.4 
( 3.6 – 11.3 ) 
18.7 
( 13.4 – 26.0 ) 
2014 Heianza Obesity 
 
Referent 
 
4.7 
( 3.9 – 5.7 ) 
2.0 
( 1.7 – 2.4 ) 
7.9 
( 6.8 – 9.2 ) 
4.7 
( 3.6 – 6.1 ) 
13.9 
( 11.6 – 16.7 ) 
2014 Heianza 
J Clin Endocrinol 
Metab 
Referent 
4.9 
( 3.2 – 7.4 ) 
1.3 
( 0.8 – 2.2 ) 
5.6 
( 3.8 – 8.3 ) 
5.9 
( 2.8 – 12.5 ) 
12.6 
( 7.9 – 20.3 ) 
 
Meta-analysis  
- 
Random Effects 
Model 
 
Referent 
4.0 
( 3.0 – 5.1 ) 
1.8 
( 1.5 – 2.2 ) 
6.2 
( 4.8 – 8.0 ) 
4.1 
( 3.3 – 5.1 ) 
10.9 
( 8.5 – 13.9 ) 
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Supplementary Table S5. Cumulative incidence of type 2 diabetes in metabolic health and body mass index 
categories after the exclusion of studies in East Asian populations. 
 
BMI category 
BMI category 
cumulative 
incidence at 5 
yearsa 
BMI category 
cumulative 
incidence at 10 
years a 
 
Risk category 
 
Proportion 
of healthy 
or 
unhealthy 
individuals 
in each 
BMI 
category 
Relative 
risk 
within 
BMI 
category 
Risk category 5 year 
cumulative incidence 
(95% CI*) 
Risk category 10 year 
cumulative incidence 
(95% CI*) 
Lean 0.3 % 0.8 % 
Metabolically 
Healthy 
Lean 
0.87 1 
0.2% 
(0.2 – 0.2%) 
0.6% 
(0.5 – 0.7%) 
Metabolically 
Unhealthy 
Lean 
0.13 3.6 
0.7% 
(0.5 – 0.9%) 
2.2% 
(1.7 – 2.8%) 
Over 
weight 
0.8 % 2.7 % 
Metabolically 
Healthy 
Overweight 
0.66 1 
0.5% 
(0.5 – 0.6%) 
1.7% 
(1.6 – 1.9%) 
Metabolically 
Unhealthy 
Overweight 
0.34 2.5 
1.3% 
(1.2 – 1.4%) 
4.4% 
(4.1 – 4.7%) 
Obese 1.8 % 5.9 % 
Metabolically 
Healthy 
Obese 
0.42 1 
1.1% 
(0.9 – 1.3%) 
3.5% 
(2.9 – 4.1%) 
Metabolically 
Unhealthy 
Obese 
0.58 2.2 
2.4% 
(2.2 – 2.6%) 
7.7% 
(7.2 – 8.1%) 
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Supplementary Figure S1. Relative risk of type 2 diabetes in different metabolic health and BMI categories compared with the metabolically healthy lean category in 
adjusted analyses.  
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Supplementary Figure S2. Representative funnel plot indicating no publication bias for the meta-analysis of type 2 diabetes risk within obese. P-value from Egger’s test = 
0.53. 
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Supplementary Figure S3. Relative risk of type 2 diabetes in metabolically healthy vs unhealthy lean 
individuals in European and East Asian populations. 
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Abstract 
Objective: Various definitions of metabolic health have been proposed to explain differences in the risk of 
type 2 diabetes within body mass index (BMI) categories. The goal of this study was to assess their 
predictive relevance.  
Research Design and Methods: We performed systematic searches of MEDLINE records for prospective 
cohort studies of type 2 diabetes risk in categories of BMI and metabolic health. In a two-stage meta-
analysis, relative risks (RR) specific to each BMI category were derived by network meta-analysis and the 
resulting RRs of each study were pooled using random effects models. Hierarchical summary receiver 
operating characteristic curves were used to assess predictive performance.  
Results: In a meta-analysis of 140,845 participants and 5,963 incident cases of type 2 diabetes from 14 
cohort studies, being classified as metabolically unhealthy was associated with higher relative risk of 
diabetes in all BMI categories (RR compared with healthy individuals [95% confidence interval, CI]: lean, 
4.0 [3.0 – 5.1]; overweight, 3.4 [2.8 – 4.3]; obese, 2.5 [2.1 – 3.0]). Metabolically healthy obese individuals 
had a high absolute risk of type 2 diabetes (10-year cumulative incidence [95% CI]: 3.1% [2.6 – 3.5%]). 
Current binary definitions of metabolic health had high specificity (pooled estimate [95% CI]: 0.88 [0.84 – 
0.91]) but low sensitivity (0.40 [0.31 – 0.49]) in lean individuals and satisfactory sensitivity (0.81 [0.76 – 
0.86]) but low specificity (0.42 [0.35 – 0.49]) in obese individuals. However, positive (< 3.3 in all BMI 
categories) and negative (> 0.4) likelihood ratios were consistent with insignificant to small improvements 
in prediction.  
Conclusions: Although individuals classified as metabolically unhealthy have a higher relative risk of type 
2 diabetes compared with individuals classified as healthy in all BMI categories, current binary definitions 
of metabolic health have limited relevance to the prediction of future type 2 diabetes.  
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  Obesity and the ‘metabolic syndrome’, two highly prevalent and often coexisting 
conditions, are major risk factors for type 2 diabetes and cardiovascular disease (1-3). The 
observation that some obese individuals have a favourable metabolic profile and appear to be 
at low risk of obesity-related complications has led to the notion of ‘metabolically healthy 
obesity’ (4,5). The topic has received much attention in recent times, with an increasing 
number of studies using definitions of metabolic health in body mass index (BMI) categories 
either as a risk factor or an outcome (5-9). 
  In the existing literature, however, there is little consensus on the definitions of 
metabolic health (4). In addition, the relevance of metabolic health definitions to the 
prediction of incident type 2 diabetes in body mass index (BMI) categories has not been 
investigated. 
 Establishing the predictive value of currently used definitions of metabolic health has 
been deemed of primary importance, as an accurate risk classification may justify selective 
preventive action in high-risk individuals (4). In addition, the construct of the ‘metabolic 
syndrome’, which is used as a basis for several definitions of metabolic health, has been 
proposed as a clinically-useful predictor of the risk of future type 2 diabetes (10). It is of 
particular interest to establish whether current definitions of metabolic health help identify 
lean individuals at high-risk of type 2 diabetes (i.e. the ‘metabolically unhealthy lean’) or 
obese individuals at low risk of type 2 diabetes (i.e. the ‘metabolically healthy obese’). 
  We therefore reviewed the literature on the definitions of metabolic health and assessed 
their relevance to the prediction of incident type 2 diabetes in lean, overweight or obese 
individuals.  
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Research Design and Methods  
Literature searches 
  This report adheres to the PRISMA guidelines, where applicable (11). We used three 
complementary strategies in order to assess the existing literature on the definitions of 
metabolic health in BMI categories. Firstly, we reviewed titles and abstracts of all references 
cited by Stefan et al. (4) and Kramer et al. (5) in recent reviews on the topic. Secondly, we 
reviewed titles and abstracts retrieved by a MEDLINE search from inception through to the 
1
st
 of September 2014 with the following terms (Search 1): ‘metabolically-healthy obesity OR 
metabolically-healthy obese OR metabolically healthy obesity OR metabolically healthy 
obese’. In order to maximise sensitivity for the detection of studies of incident type 2 
diabetes, we conducted a second MEDLINE search from 2000 to the 1
st
 of September 2014 
with the following strategy (Search 2): ‘(Diabetes Mellitus, Type 2[MeSH Terms] OR “type 2 
diabetes”[Title/abstract] OR “diabetes”[Title] OR Type II Diabetes Mellitus OR Type 2 
Diabetes Mellitus OR Noninsulin-Dependent Diabetes Mellitus OR Diabetes Mellitus, Type II 
OR Diabetes Mellitus, Type 2 NOT “type 1 diabetes”[Title/abstract]) AND (adiposity OR 
“body mass index”[MeSH Terms] OR body mass index[Text Word] OR “overweight”[MeSH 
Terms] OR overweight[Text Word] OR “obesity”[MeSH Terms] OR obesity[Text Word]) 
AND (metabolic health OR metabolically healthy OR metabolic status OR high risk OR risk 
category OR risk stratification OR cardiometabolic health OR cardiometabolic risk) AND 
(epidemiologic studies[MeSH Terms] OR epidemiologic study OR observational study OR 
case-control OR cross-sectional OR case-cohort OR longitudinal study OR cohort OR cohort 
study OR follow-up study OR cohort analysis OR incidence study) AND (humans[MeSH 
Terms]) AND ("2000"[Date - Publication] : "3000"[Date - Publication]) AND 
English[Language]’.  
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  Titles, abstracts and full articles were reviewed by one author (L.A.L.) with the 
following criteria. For title review, the title had to refer to the definition of metabolic health 
or cardio-metabolic risk stratification in lean, obese or overweight individuals. For abstract 
and full-article reviews, the following inclusion criteria were used: (a) the study had cross-
sectional, case-control, cohort, cohort-derived design (nested case-control or case-cohort); (b) 
the study provided an explicit definition of metabolic health in lean, overweight or obese 
individuals or used one or more variables to stratify cardiometabolic risk in these categories. 
Exclusion criteria were as follows: (a) the manuscript reported a randomised controlled trial, 
another intervention study (e.g. life-style interventions or studies on individuals who were 
candidate to bariatric surgery) or a review of the literature; (b) the study used obesity, BMI, 
or another anthropometric variable as the risk factor or as the outcome, rather than stratifying 
variable; (c) the study was restricted to metabolically healthy or unhealthy individuals only, 
was not conducted in adult humans, was a genetic association study, or was restricted to 
patients with diabetes or other cardio-metabolic disease. 
 One author (A.S.) was asked to independently review 10% of the records of each stage of 
each search. Inconsistencies were resolved by repeated review and discussion. Concordance 
was high (96% for titles, n = 256/269; 97% for abstracts, n = 68/70; 100% for articles, n = 
18/18). Data on definitions of metabolic health from all screened articles (n = 126) and full 
information from articles reporting on incident type 2 diabetes (n = 16) were extracted. 
Studies on incident type 2 diabetes were qualitatively assessed using a modified version of 
the scoring system proposed by Bell et al. in a recent review (6).  
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Definition of BMI and metabolic health categories in studies of incident type 2 diabetes 
 For studies in non-East Asians, BMI categories were defined as follows: lean < 25, 
overweight 25-29.9 and obese ≥ 30 kg/m
2 
(12). For East Asians, we used categories of BMI 
associated with ‘acceptable, increased and high’ risk of metabolic disease according to a 
recent communication of the World Health Organization, i.e. lean < 23, overweight 23-27.4 
and obese ≥ 27.5 kg/m
2 
(13). Where the authors did not use these cut-offs, we contacted them 
using a standardised electronic mail message and asked for a reclassification of the 
participants.   
  Metabolic health definitions, mainly consisting of insulin resistance and metabolic 
syndrome, were carried over from the original reports.  
  
Two-stage meta-analysis 
 Our meta-analysis was conducted in two stages. In the first stage, we used network meta-
analysis to derive, for each study, the relative risk (RR) of type 2 diabetes of metabolically 
unhealthy compared with healthy individuals in the lean, overweight and obese categories. In 
the second stage, we pooled the resulting RRs using random effects models 
 
Network meta-analysis 
  The primary objectives of this study were to (a) assess the risk of type 2 diabetes 
associated with current definitions of metabolic health within the lean, overweight and obese 
categories and (b) to assess the predictive relevance of these definitions. However, only one 
study (14) reported RR comparing unhealthy and healthy individuals within each BMI 
category. In all the other instances, articles reported the risk of all groups relative to the 
metabolically healthy lean (6,15-28). These comparisons may be of limited value when 
assessing the predictive relevance of metabolic health definitions. For instance, a comparison 
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of metabolically unhealthy obese vs metabolically healthy lean simultaneously evaluates the 
contribution of two risk factors (i.e. BMI and level of metabolic health).  
  In instances where there was a need to contact the authors for clarifications, we asked for 
additional analyses within BMI categories (see Supplementary Table S1). When there was no 
need to contact authors, we inferred the RR in the overweight and obese categories using 
network meta-analysis within each study (Supplementary Table S1 and Text). Network meta-
analysis is a meta-analysis approach allowing indirect comparison of evidence, which has 
previously been applied in the context of randomised controlled trials (29,30). Here, we used 
this method in order to estimate, for each study, the RR of metabolically unhealthy vs healthy 
individuals in the overweight and obese categories. To do this, we used the comparisons with 
the metabolically healthy lean category as input evidence (Supplementary Text).  
 
Meta-analysis of relative risk estimates 
  In the second stage of our meta-analysis, adjusted estimates of RR were pooled across 
studies using random effects models. Random effects models were used because of the 
heterogeneity in the definitions of metabolic health. Analyses were stratified by sex (i.e. 
studies with proportion of women ≤ 30% vs all other studies), age (i.e. mean or median age in 
the 3
rd
 or 4
th
 decade vs 5
th
 or 6
th
 decade), country or population (i.e. non-East Asian vs East 
Asian; European vs other non-East Asian vs East Asian), definition of metabolic health (i.e. 
metabolic syndrome vs insulin resistance), sample size (i.e. below vs above 5,000 
participants), length of follow-up (below vs above 7 years of mean or median follow-up) or 
extent of adjustment (i.e. crude or minimal vs extensive). Because three of the sixteen 
selected studies were conducted in the same source population with overlapping but not 
identical criteria of selection and follow-up periods, only the largest of these studies was 
included in the main analysis. Analyses with either of the other two studies, instead of the 
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largest, yielded comparable results (Supplementary Table S2). In studies using more than one 
definition, we arbitrarily chose one for inclusion in our main analysis. In doing so, we chose 
those analyses using metabolic syndrome as a criterion for the definition of metabolic health 
(i.e. in the instance of Meigs et al. (18) and Arnlöv et al. (19)) and those with more relaxed 
criteria for the definition of metabolic health (i.e. in the instance of Bell et al.(6)). Egger’s test 
and funnel plots were used to assess publication bias. The I-squared statistic was used to 
quantify heterogeneity. The source of heterogeneity was investigated by the aforementioned 
stratified analyses. 
 
Absolute type 2 diabetes risk estimation 
  The cumulative incidence of type 2 diabetes in metabolic health and BMI categories was 
estimated using a probabilistic analysis (20,000 simulations), which simultaneously 
incorporates the uncertainty in the estimates of each of the input parameters. Input parameters 
in the model were (a) the proportion of participants who were metabolically healthy within 
each of the three BMI categories in our meta-analysis of 140,845 participants; (b) the RR of 
type 2 diabetes within each BMI category as estimated by our random effects model meta-
analysis and (c) the cumulative incidence of type 2 diabetes at 5- and 10-years of follow-up 
from the EPIC InterAct case-cohort study (31).  
 
Predictive relevance 
  The predictive relevance of metabolic health definitions was studied by hierarchical 
summary receiver operating characteristic curves and Fagan’s nomograms. The meta-analysis 
of predictive test accuracy was performed by fitting a two-level mixed effects logistic 
regression model, with independent binomial distributions for the true positives and true 
negatives conditional on the sensitivity and specificity in each study, and a bivariate normal 
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model for the logit transforms of sensitivity and specificity between studies. Sensitivity and 
specificity were expressed as proportions and their use in this study pertains to the prediction 
of future disease in diabetes-free individuals. Fagan’s nomograms represent the predictive 
performance of a test with lines intercepting three parallel vertical axes. The leftmost axis 
indicates the pre-test probability of disease, the rightmost axis the post-test probability and 
the central axis the positive or negative likelihood ratio. Lines are then drawn from the pre-
test probability on the left through the likelihood ratio in the centre and extended to the 
posterior probabilities on the right to represent scenarios of a positive or negative test result 
in each of the three BMI categories. Likelihood ratios were used to evaluate contribution to 
prediction using cut-offs recommended by the authors of the fagan STATA package (32). 
 
Statistical analysis 
 Analyses were carried out using STATA v13.1 (StataCorp, College Station, Texas 77845 
USA). The network package was used for network meta-analysis (30), metan for random 
effects model meta-analysis (33), metandi (32) and fagan (URL: http://fmwww.bc.edu/repec/ 
/bocode/f/fagan.ado; author, Ben Dwamena, Division of Nuclear Medicine, Department  of 
Radiology, University of Michigan Health System, Ann Arbor, USA) for meta-analysis of 
predictive test accuracy (32). The probabilistic analysis for estimation of cumulative 
incidences was carried out using openBUGS (34). 
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Results 
Literature search 
 Figure 1 depicts the literature search workflow. A total of 3122 MEDLINE records were 
reviewed and 126 articles matching our search criteria were selected for data extraction. The 
articles reported a total of 177 analyses using a definition of metabolic heath. Definitions of 
metabolic health were mostly binary (i.e. healthy or unhealthy) and fell into five broad 
categories: (a) metabolic syndrome, (b) metabolic syndrome combined with insulin resistance 
or other criteria, (c) insulin resistance, (d) cardiorespiratory fitness, (e) miscellaneous. 
Metabolic syndrome defined according to the Adult Treatment Panel III criteria (35), insulin 
resistance according to the homeostatic model assessment
 
(36) and combined definitions 
provided by Wildman et al. (7) and Karelis et al. (8) were most frequently used. 
Supplementary Table S3 reports the breakdown of the 177 definitions into these five broad 
categories.  
 We identified a total of sixteen manuscripts reporting on cohort studies of incident type 2 
diabetes in BMI and metabolic health categories (Table 1) (6,14-28). Studies were mostly 
population-based cohort studies in middle-aged individuals with a mean or median follow-up 
ranging from 4 to 17.5 years. Qualitative assessment revealed generally high quality (Table 
1). In the main analysis, we retained only the largest (25) of three studies that investigated the 
same source population (16,25,28). A total of fourteen studies, comprising 140,845 
participants and 5963 incident cases, were included in the quantitative meta-analysis 
(6,14,15,17-27).  
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Network meta-analysis and random effects meta-analysis of relative risk estimates 
 In a meta-analysis of type 2 diabetes risk within BMI and metabolic health categories, all 
groups had higher risk when compared to the healthy lean group (RR [95% confidence 
interval, CI]: metabolically unhealthy lean group, 4.0 [3.0 – 5.1]; metabolically healthy 
overweight group, 1.8 [1.5 – 2.2]; metabolically unhealthy overweight group, 6.2 [ 4.8 – 8.0]; 
metabolically healthy obese group, 4.1 [3.3 – 5.1]; metabolically unhealthy obese group, 10.9 
[8.5 – 13.9]; see also Supplementary Table S4 and Figure S1). 
 Where analysis results were not available from the manuscript or from direct contact 
with the authors, network meta-analysis was used to derive within-overweight and within-
obese category RRs and 95% CI. In instances where both estimates were available, the 
central estimate of RR provided by the authors strongly correlated with that obtained by 
network meta-analysis (average r
2
 > 0.95; n = 18; see Supplementary Table S1). The relative 
risks obtained in this first stage were then pooled using random effects meta-analysis. 
Random effects meta-analysis revealed that – when compared with healthy individuals – 
metabolically unhealthy individuals are at higher risk of type 2 diabetes in all BMI categories 
(RR compared with healthy individuals [95%, CI]: lean, 4.0 [3.0 – 5.1], N at risk / type 2 diabetes = 
67,281 / 1,393; overweight, 3.4 [2.8 – 4.3], N at risk / type 2 diabetes = 58,060 / 2,903; obese, 2.5 
[2.1 – 3.0], N at risk / type 2 diabetes = 15,504 / 1,667; see Figure 2). The relative risk of type 2 
diabetes associated with being classified as unhealthy was highest in the lean category and 
lowest in the obese category. Funnel plots and Egger’s test (P > 0.1 for all comparisons) 
indicated no publication bias (Supplementary Figure S2). There was heterogeneity between 
studies in the estimated RR within the lean and overweight categories, but not the obese 
category (Figure 2). Stratified analyses revealed that ethnicity was likely the driver of 
heterogeneity, with RR higher in East Asian populations in all BMI categories (Figure 2). 
Further stratification for geographic region (European vs East Asian studies) resolved 
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residual heterogeneity in estimates in the lean category (Supplementary Figure S3). Results 
were similar in studies using metabolic syndrome or insulin resistance as definitions for 
metabolic health. 
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Absolute type 2 diabetes risk estimation and predictive relevance 
 Using a probabilistic analysis, which simultaneously incorporates uncertainty in all the 
input parameter estimates, we estimated the cumulative incidence of type 2 diabetes at 5 and 
10 years in all BMI and metabolic health categories (Table 2). Metabolically healthy obese 
individuals had a cumulative incidence of type 2 diabetes over 10 years of 3.1% (95% CI: 2.6 
– 3.5%). Cumulative incidence estimates from a sensitivity analysis after exclusion of studies 
in East Asian populations were largely overlapping with those of the main analysis 
(Supplementary Table S5).  
 Hierarchical summary receiver operating curve analysis revealed increasing sensitivity 
and decreasing specificity in higher BMI categories (Figure 3A-C). In lean individuals, 
testing metabolic health was not sensitive (pooled estimate [95% CI]: 0.40 [0.31 – 0.49]), but 
was specific (0.88 [0.84 – 0.91]). In overweight individuals, both sensitivity (0.65 [0.56 – 
0.74]) and specificity (0.68 [0.61 – 0.74]) were low. In obese individuals, sensitivity was 
acceptable (0.81 [0.76 – 0.86]), but specificity (0.42 [0.35 – 0.49]) was low. The pooled 
estimates of the positive likelihood ratio were 3.3 (95% CI:  2.7 – 3.9) in lean category, 2.0 
(1.8 – 2.3) in the overweight category and 1.4 (1.3 – 1.5) in the obese category. The pooled 
estimates for the negative likelihood ratio were 0.7 (95% CI: 0.6 – 0.8) in the lean category, 
0.5 (0.4 – 0.6) in the overweight category and 0.5 (0.4 – 0.5) in the obese category. These 
likelihood ratios show that current binary definitions of metabolic health make only small or 
insignificant contributions to the prediction of future type 2 diabetes in BMI categories 
(Figure 3D-E). 
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Discussion 
 In this study, we reviewed definitions of metabolic health, which have been used to 
classify the risk of metabolic disease in BMI categories. We also sought to assess the risk of 
type 2 diabetes associated with being classified as metabolically unhealthy in lean, 
overweight and obese individuals. We found that being classified as metabolically unhealthy 
is associated with higher risk of type 2 diabetes relative to the healthy group in all categories 
of BMI.  
 Our study is the largest meta-analysis of the risk of type 2 diabetes associated with 
metabolic health definitions and the only one to have assessed risk within BMI categories. In 
a meta-analysis by Bell et al. (6) of eight studies, with a total of 27,982 participants, relative 
risk was calculated using the healthy lean category as a reference. This is not informative 
about the risk of type 2 diabetes within BMI categories or the predictive relevance of 
metabolic health definitions. In this study, we obtained within BMI-category risk estimates 
using network meta-analysis, a method for the pooling of indirect evidence used in meta-
analyses of randomised controlled trials. The method accurately estimated the relative risk in 
BMI categories, with a loss of precision, due to the uncertainty of indirect estimations, which 
was offset by the large overall sample size of this meta-analysis. Using this method, we were 
able to show that the relative risk of type 2 diabetes is higher in all categories of BMI for 
metabolically unhealthy individuals compared with those who are classified as metabolically 
healthy. Relative risks within the lean and overweight categories were higher in East Asian 
populations. This probably reflects the higher prevalence of abdominal obesity and insulin 
resistance in these populations compared with Europeans at a given level of BMI (37, 38). 
 However, relative risk only partially accounts for the predictive relevance of a given 
definition. Predictive relevance has to be evaluated also in the context of absolute risk. The 
absolute risk of individuals deemed to be ‘metabolically healthy obese’ was high, with an 
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estimated cumulative incidence of type 2 diabetes over 10 years exceeding 3%. This raises 
doubts about the predictive value of currently used binary definitions of metabolic health. An 
analysis of hierarchical summary receiver operating characteristics curve and Fagan’s 
nomograms revealed limited predictive relevance in all three BMI categories.  
 Metabolic health definitions had a predictive performance opposite of the desirable, with 
low sensitivity in the lean category and low specificity in the obese category. In the lean 
category, metabolic health definitions had high specificity and could therefore be considered 
as a confirmatory test. However, there is presently no screening test to identify at-risk lean 
individuals in the population. With an absolute risk of 2.2% at 10 years, one would argue that 
metabolically unhealthy lean individuals would not be candidates for particular preventive 
measures besides those recommended for the general population. In overweight individuals, 
current binary definitions of metabolic health had low sensitivity and specificity. The 
metabolically healthy overweight individuals had an absolute risk of type 2 diabetes greater 
than that of the lean category and the metabolically unhealthy overweight individuals an 
absolute risk smaller than that of the obese category. In addition, the metabolically unhealthy 
overweight group accounted for 40% of the overweight category, which is in many countries 
the largest BMI category in the general population. Therefore, it is difficult to conceive 
preventive measures that could efficiently target such a large portion of the population. In 
obese individuals, using current metabolic health definitions may be sensitive. However, 
specificity in this group was well below acceptable levels and ‘metabolically healthy’ obese 
individuals still had an absolute risk greater than that of the overweight category.  
 In addition to these limitations, defining metabolic health entails invasive biological 
sampling for the measurement of biomarkers such as glucose, triglycerides, high-density 
lipoprotein cholesterol or insulin. In particular, the criteria for some of the definitions of 
metabolic health include fasting glucose, which is a major predictor of type 2 diabetes (3739). 
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Therefore, the value of using any of the other criteria (e.g. high-density lipoprotein 
cholesterol or triglycerides) included in these definitions in addition to fasting glucose is 
likely to be limited. Overall, there is little support for use of these definitions for the 
prediction or classification of type 2 diabetes risk in BMI categories. These considerations 
apply to currently-used binary definitions of metabolic health. It is possible that more 
comprehensive approaches to the definition of metabolic health may yield better predictive 
performance. Also, our meta-analytic approach pooled evidence from studies using different 
definitions of metabolic health. However, our analytical approach accounted for possible 
differences in the performance of definitions of metabolic health used in the constituent 
studies of the meta-analysis.   
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Conclusions 
  In conclusion, in a meta-analysis of 140,845 participants, being classified as 
metabolically unhealthy as compared with healthy using current binary definitions of 
metabolic health was associated with higher relative risk of type 2 diabetes in all BMI 
categories. However, when considering predictive performance in the context of absolute 
risk, we found that current binary definitions of metabolic health have limited predictive 
relevance. Our study does not support the use of current definitions of metabolic health for 
the prediction or classification of type 2 diabetes risk.  
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Figure Legends 
Figure 1. Workflow of the review. MHO indicates metabolically healthy obesity; a, Search 2 as described in 
the Methods section; b, Search 1, as described in the methods section; c, article restricted to unhealthy lean or 
used BMI as the endpoint/only risk factor rather than stratifying variable. 
Figure 2. Relative risk of type 2 diabetes in metabolically unhealthy compared with healthy individuals by 
body mass index category and country (non-East Asian or East Asian). 
Figure 3. Performance of metabolic health definitions in the prediction of future development of type 2 
diabetes. The top Panels report hierarchical summary receiver operating characteristic (HSROC) curves of the 
predictive performance in lean (Panel A), overweight (Panel B) and obese (Panel C) individuals. Solid squares 
represent pooled estimates; open circles, individual study estimates with a size that is proportional to the weight 
of each study; solid lines, HSROC curves; broken lines delimit uncertainty in the estimates of the summary 
points (95% confidence region) or of the HSROC curves (95% prediction region). In Panels D and E, Fagan’s 
nomograms represent scenarios of positive (i.e. metabolically unhealthy; Panel D) or negative (i.e. metabolically 
healthy individual; Panel E) results of the binary classification of metabolic health in body mass index 
categories.  
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Tables 
 
Table 1. Cohort studies investigating incident type 2 diabetes in metabolic health and body mass index categories. 
First Author 
Year; 
Pubmed ID 
Country /  
years of 
recruitment 
Definition of metabolic healtha 
Definition of 
BMI 
categories, in 
kg/m2 
Study population 
Sample size 
and incident 
cases 
(Ntotal/NT2D) 
Incident T2D 
ascertainment 
Length of 
follow-up 
Adjustment 
Quality 
scoreb 
Meigs 
2006; 
16735483 
Framingham 
Offspring 
Study, 
USA 
1991-1995 
 
(1) MetS, 3 / 5 ATPIII criteria: FG < 
5.6, WC ≤ 88 102 M or 88 W, TG < 
1.7, HDL ≥ 1 M or 1.3 W, BP < 
130/85 
 
(2) IR: HOMA-IR ≤ 75th percentile 
of distribution in subjects without 
T2D 
 
Lean < 25  
OW 25-29.9  
Obese ≥ 30 
 
Offspring of community-based 
study; European ancestry; free 
from CVD and T2D at 
baseline; mean age, 54 years; 
women, 55% 
 
(1) 2902 / 141 
(2) 2803 / 135 
FG ≥ 7.0 mmol/L or 
new use of 
hypoglycaemic 
therapy 
Mean 6.8 
years 
Age, sex, family history 
of diabetes, and impaired 
glucose tolerance 
6 
Arnlöv 
2011; 
20852030 
Uppsala 
Longitudinal 
Study of Adult 
Men, 
Sweden 
1970-1973 
 
(1) MetS: 3 / 5 ATPIII criteria: FG 
< 6.1c, BMI ≥  29.4d,TG < 1.7, 
HDL ≥ 1.04, BP < 130/85 
 
(2) IR: HOMA-IR ≤ 75th 
percentile of distribution in 
subjects without T2D, i.e. 3.43 
 
Lean < 25 OW 
25-30  
Obese > 30 
Community-based study of 
men born in 1920-1924 free 
from T2D at baseline; mean 
age, 50 years, women, 0% 
(1) 1675 / 160 
(2) 1385 / 117 
FG ≥ 7.0 mmol/L at 
follow-up or data from 
national hospital-
discharge registry 
Up to 20 
years 
Age, smoking status, and 
level of physical activity 
6 
Hadaegh 
2011; 
21609497 
 
Tehran Lipid 
and Glucose 
Study, 
Iran 
1999-2001 
 
MetS: 3 / 5 harmonised criteria: FG 
< 5.5, WC < 94.5, TG < 1.7, HDL ≥ 
1.04 M or 1.3 W, BP < 130/85 
Lean < 25  
OW 25-29.9  
Obese ≥ 30 
Population based cohort study 
in Tehran; mean age, 42 years;  
women, 58% 
5,250 / 369 
Self-reported or 
OGTT-based at two 
follow-up visits 
Median 6.5 
years 
Age, family history of 
T2D, history of CVD, 
education, smoking 
status 
6 
Kim 
2012; 
22621338 
South Korea 
2005 
MetS: 3 / 5 2009 
harmonised criteria: FG < 5.6, WC < 
90 M or 80 W, TG < 1.7, HDL ≥ 1 
M or 1.3 W, BP < 130/85 
Lean < 23  
OW 23-27.4  
Obese ≥ 27.5 
 
Subjects attending baseline and 
follow-up visits at Health 
Promotion Centre; mean age, 
48 years; women, 35% 
 
8,748 / 308 
FG ≥ 7.0 mmol/L or 
HbA1c ≥ 6.5% or 
treatment 
5 years 
Age, sex, smoking, 
alcohol consumption, 
and physical activity 
6 
Bo 
2012; 
23034958 
Italy 
2001-2003 
MetS plus IR: 3 / 5 harmonised 
criteria: FG < 5.6, WC < 94 M or 80 
W, TG < 1.7, HDL ≥ 1 M or 1.3 W, 
BP < 130/85 
AND 
HOMA-IR < 2.5 
Lean < 25  
OW 25-30  
Obese > 30 
Caucasian volunteers from 
Local Health Units; mean age, 
54 years; women, 53% 
1,658 / 72 
Self-reported, FG, 
demographic registries 
9 years Nonee 6 
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Table 1. (Continued I) 
 
First Author 
Year; 
Pubmed ID 
Country /  
years of 
recruitment 
Definition of metabolic healtha 
Definition of 
BMI categories, 
in kg/m2 
Study population 
Sample size 
and incident 
cases 
(Ntotal/NT2D) 
Incident T2D 
ascertainment 
Length of 
follow-up 
Adjustment 
Quality 
scoreb 
Appleton 
2013; 
23491523 
 
North West 
Adelaide Health 
Study, 
Australia 
1999-2003 
 
MetS: 3 / 4 IDF criteria: FG < 5.6, 
TG < 1.7, HDL ≥ 1 M or 1.3 W, BP 
< 130/85 
Lean 18.5-24.9 
OW 25-29.9  
Obese ≥ 30 
Community-based study; 
Adults of European ancestry; 
free from T2D and CVD at 
baseline; mean age,  42 
yearsf; womenf, 57% 
2315 / 112 
Self-reported doctor 
diagnosis or FG ≥ 7.0 
mmol/L 
Median 8.2 
years 
Age, sex, 
household income, and 
family history of 
diabetes 
6 
Soriguer 
2013; 
23559087 
 
Prospective 
Pizarra Study, 
Spain  
1997-1998 
 
 
MetS plus IR: 3 / 3 criteria: FG < 
6.1, TG < 1.7, HOMA-IR < 90th 
percentileg 
 
Lean < 25  
OW 25-29.9  
Obese ≥ 30 
Population-based cohort 
study; mean age, 40 years; 
women, 62%h 
387 / 38e 
Self-reported or FG at 
follow-up 
11 years Age, sexe 5 
Aung 
2014; 
24257907 
San Antonio 
Heart Study, 
USA 
1979-1988 
 
MetS plus IR: 4 / 5 criteria: FG < 
5.6, TG < 1.7, HDL ≥ 1 M or 1.3 W, 
BP < 130/85, HOMA-IR ≤ 5.13 
  
Lean < 25  
OW 25-29.9  
Obese ≥ 30 
 
Population based cohort 
study of Mexican and 
Caucasian Americans; mean 
age, 42 years; women, 57% 
 
2,814 / 262 
OGTT or medication 
at follow-up 
Median 7.4 
years 
Age, sex, ethnicity, 
family history of 
diabetes, fasting glucose 
6 
Sung 
2012; 
24361070 
South Korea 
2003 
IR: HOMA-IR < 2, i.e. 75th 
percentile 
Lean < 23  
OW 23-27.49  
Obese ≥ 27.5e 
Participants of health 
examination at hospital; 
mean age, 41 years; women, 
29% 
12,853 / 223 
Self-reported, medical 
history or FG at 
follow-up 
5 years 
 
Age, sex, alcohol, 
smoking status, exercise, 
educational status, 
baseline glucosee 
 
5 
Bell 
2014; 
24661566 
English 
Longitudinal 
Study of 
Ageing, 
UK 
2004-2005 
 
(1) MetS plus CRP: 3 / 5 
customised criteria: Hba1c < 
6%, TG < 1.7, HDL ≥ 1 M or 
1.3, BP < 130/85, CRP < 0.3 
mg/dL 
 
(2) MetS plus CRP: 4 / 5 of the 
criteria used in definition (1) 
 
Lean < 25  
OW 25-29.9  
Obese ≥ 30 
Population-based cohort 
study; mean age, 65 years; 
women, 57% 
3,060 / 138 
Self-reported 
physician diagnosis 
Mean 5.9 
years 
 
Age, sex, smoking, 
alcohol intake, physical 
activity, wealth, 
depressive symptoms 
 
5 
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Table 1. (Continued II) 
 
First 
Author 
Year; 
Pubmed ID 
Country /  
years of 
recruitment 
Definition of metabolic 
health
a
 
Definition of 
BMI 
categories, in 
kg/m2 
Study population 
Sample size 
and incident 
cases 
(Ntotal/NT2D) 
Incident T2D 
ascertainment 
Length of 
follow-up 
Adjustment 
Quality 
scoreb 
Hinnouho 
2014; 
24670711 
Whitehall II 
Study, 
UK 
1991-1993 
MetS: 3 / 4 ATPIII criteria: FG < 
5.6, TG < 1.7, HDL ≥ 1.04 M or 
1.29 W, BP < 130/85 
Lean 18.5-24.9  
OW 25-29.9  
Obese ≥ 30 
Cohort study of office 
workers in central London; 
mean age, 49 years; 
women, 30% 
7,122 / 798 
OGTT, physician 
diagnosis or use of 
medication at follow-
up 
Median 17.5 
years 
 
Sex, socioeconomic 
status, marital status, 
ethnicity, physical 
activity, smoking, 
alcohol, fruits and 
vegetables consumption, 
CVD medications and 
procedures 
 
6 
Heianza 
2014 
J Clin 
Endocrinol 
Metab; 
24823457 
 
Toranomon 
Hospital Health 
Management 
Centre Study, 
Japan 
1997-2002 
 
MetS: 3 / 4 IDF criteria: FG < 5.6, 
TG < 1.7, HDL ≥ 1.03 M or 1.29 
W, BP < 130/85 
Lean < 23  
OW 23-27.4  
Obese ≥ 27.5e 
 
Cohort Study of Japanese 
government employees; 
mean age, 48 years; 
women, 27% 
 
8,090 / 274e 
FG ≥ 7, Hba1c ≥ 
6.5%, or self-reported 
5 years 
Age, sex, smoking, 
physical activity, alcohol 
intake, family history of 
diabetese 
6 
Rhee  
2014; 
24870949 
South Korea 
2005 
MetS plus IR: 3 / 4 criteria: FG < 
5.6, TG < 1.7, HDL ≥ 1 M or 1.3 
W, BP < 130/85 AND  
HOMA-IR < 90th percentile  
Lean < 23  
OW 23-27.4  
Obese ≥ 27.5e 
 
Participants of medical 
check-up programme; 
mean age, 43 years; 
women, 27% 
 
6,748 / 277 
FG, Hba1c or self-
reported history or 
medication 
4 years 
 
Age, sex, ALT, 
creatinine, total 
cholesterol, hs-CRPe 
 
6 
Heianza 
2014 
Obesity; 
25131796 
Japan 
1999-2004 
MetS: 3 / 4 IDF criteria: FG < 5.6, 
TG < 1.7, HDL ≥ 1.03 M or 1.29 
W, BP < 130/85 
Lean < 23  
OW 23-27.4  
Obese ≥ 27.5e 
 
Cohort Study of 
individuals occupational 
health examinations; mean 
age, 47 years; women, 36% 
 
27,891 / 1,668e 
FG ≥ 7, Hba1c ≥ 
6.5%, or self-reported 
8 years 
Age, sex, smoking, 
physical activitye 
6 
Twig 
2014; 
25139886 
Metabolic, 
Lifestyle and 
Nutrition 
Assessment in 
Young Adults, 
Israel 
1995-2011 
MetS: 3 / 4 ATPIII criteria: FG < 
5.6, TG < 1.7, HDL ≥ 1, BP < 
130/85 e,i 
Lean < 25  
OW 25-29.9  
Obese ≥ 30 
Cohort study of men from 
the Israel Defence Forces; 
mean age, 31 years; 
women, 0% 
33,939 / 734 
FG or physician 
diagnosis 
Median 6.1 
years 
Age, family history of 
diabetes, country of 
origin, WBCe 
6 
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Table 1. (Continued III) 
 
First 
Author 
Year; 
Pubmed ID 
Country /  
years of 
recruitment 
Definition of metabolic 
health
a
 
Definition of 
BMI categories, 
in kg/m2 
Study population 
Sample size 
and incident 
cases 
(Ntotal/NT2D) 
Incident T2D 
ascertainment 
Length of 
follow-up 
Adjustment 
Quality 
scoreb 
Jung 
2014; 
25155902 
South Korea 
2005-2006 
MetS: 4 / 4 IDF criteria: FG < 5.6, 
TG < 1.7, HDL ≥ 1 M or 1.3 W, BP 
< 130/85 
Lean < 23  
OW 23-27.4  
Obese ≥ 27.5e 
 
Cohort study of employees 
of large Korean company 
and their spouses; mean 
age, 37 years; women, 44% 
 
34,994 / 889e 
FG ≥ 7, Hba1c ≥ 
6.5% or medication 
5 years 
Age, sex, smoking, 
alcohol intake, physical 
activitye 
6 
  
Abbreviations: BMI, body mass index; T2D, type 2 diabetes; MetS, metabolic syndrome; IR, insulin resistance; HOMA-IR, Homeostatic model assessment – insulin resistance; ATPIII, Adult Treatment Panel III; FG, fasting glucose; TG, 
triglycerides; HDL, high-density lipoprotein cholesterol; BP, blood pressure; WC, waist circumference; M, men; W, women; OW, overweight; OGTT, oral glucose tolerance test; WBC, white blood cells; IDF, International Diabetes Federation; 
CVD, cardiovascular disease; hs-CRP, high-sensitivity C-reactive protein. 
Notes: a All cut-off values expressed as cm for waist circumference, mmol/L for fasting glucose, HDL cholesterol or triglycerides, kg/m2 for BMI and mmHg for blood pressure. In some studies treatment with medication (e.g. anti-hypertensive 
drugs) was used as a complementary factor to adjudicate metabolic risk criteria. b We used a quality score similar to the one reported by Bell et al. Study quality was assessed according to the definition of exposure, outcome and to the extent of 
adjustment. Points were assigned as follows: 2 points if the study considered metabolic risk factor clustering as in the metabolic syndrome; 1 point if the study considered insulin resistance only; 2 points if diabetes diagnosis was based on 
objective clinical measurements (e.g. fasting or two hour glucose levels); 1 point if diabetes adjudication was based on self-report only; 2 points for extensive adjustment, i.e. age, sex plus at least two of the following, family history of diabetes, 
ethnicity, alcohol consumption, smoking status, physical activity, dietary habits and socioeconomic status, impaired glucose tolerance status; 1 point for basic adjustment, i.e. age and sex; 0 points for crude estimates. Studies were scored out of 
6 possible points. Adjustment in the original report was used to adjudicate the extent of adjustment. c Of fasting blood glucose, corresponding to fasting plasma glucose of 5.6 mmol/L. d BMI used in lieu of waist circumference criterion. e 
Information as reported by the authors in a personal communication. f Average of metabolically healthy lean, metabolically healthy obese, metabolically unhealthy obese groups. g The authors reported 4 different definitions of metabolic health. 
Here we report the one we used in the meta-analysis, for which the authors provided detailed results of type 2 diabetes incidence in a personal communication. h In the full baseline study. i In the original report metabolic health was the absence 
of any metabolic syndrome criteria and the risk of type 2 diabetes was evaluated for individuals with 1, 2, 3 or more criteria separately
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Table 2. Cumulative incidence of type 2 diabetes in metabolic health and body mass index categories. 
 
BMI category 
BMI category 
cumulative 
incidence at 5 
yearsa 
BMI category 
cumulative 
incidence at 10 
years a 
 
Risk category 
 
Proportion 
of healthy 
or 
unhealthy 
individuals 
in each 
BMI 
category 
Relative 
risk 
within 
BMI 
category 
Risk category 5 year 
cumulative incidence 
(95% CI*) 
Risk category 10 year 
cumulative incidence 
(95% CI*) 
Lean 0.3 % 0.8 % 
Metabolically 
Healthy 
Lean 
0.82 1 
0.2% 
(0.1 – 0.2%) 
0.5% 
(0.5 – 0.6%) 
Metabolically 
Unhealthy 
Lean 
0.18 4.0 
0.6% 
(0.6 – 0.8%) 
2.2% 
(1.9 – 2.5%) 
Over 
weight 
0.8 % 2.7 % 
Metabolically 
Healthy 
Overweight 
0.59 1 
0.4% 
(0.3 – 0.5%) 
1.3% 
(1.1 – 1.6%) 
Metabolically 
Unhealthy 
Overweight 
0.41 3.4 
1.4% 
(1.3 – 1.5%) 
4.5% 
(4.2 – 4.9%) 
Obese 1.8 % 5.9 % 
Metabolically 
Healthy 
Obese 
0.38 1 
1.0% 
(0.8 – 1.1%) 
3.1% 
(2.6 – 3.5%) 
Metabolically 
Unhealthy 
Obese 
0.62 2.5 
2.4% 
(2.2 – 2.5%) 
7.6% 
(7.3 – 8.0%) 
BMI, body mass index; CI, confidence interval. 
a From the EPIC InterAct Study 
*derived via a probabilistic analysis, which simultaneously incorporates the uncertainty in each of the parameter estimate (openBUGS, 
20000 simulations) 
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